期刊文献+

Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro 被引量:5

Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro
下载PDF
导出
摘要 AIM: To explore the effects of mifepristone, a progesterone receptor (PR) antagonist, on the proliferation of human gastric adenocarcinoma cell line SGC-7 901 in vitro and the possible mechanisms involved.METHODS: In situ hybridization was used to detect the expression of PR mRNA in SGC-7 901 cells. After treatment with various concentrations of mifepristone (2.5, 5, 10,20μmol/L) at various time intervals, the ultrastructural changes, cell proliferation, cell-cycle phase distribution, and the expression of caspase-3 and Bcl-XL were analyzed using transmission electron microscopy (TEM), tetrazolium blue (MTT) assay, ^3H-TdR incorporation, flow cytometry, and reverse transcription-polymerase chain reaction (RT-PCR).RESULTS: Mifepristone markedly induced apoptosis and inhibited cell proliferation of PR- positive SGC-7 901 cells revealed by TEM, MTT assay and ^3H-TdR incorporation, in a dose- and time-dependent manner. The inhibitory rate was increased from 8.98% to 51.29%. Flow cytometric analysis showed mifepristone dose-dependently decreased cells in S and G2/M phases, increased cells in G0/G1 phase,reduced the proliferative index from 57.75% to 22.83%.In addition, mifepristone up-regulated the expression of caspase-3, and down- regulated the Bcl-XL expression,dose-dependently.CONCLUSION: Mifepristone effectively inhibited the proliferation of PR-positive human gastric adenocarcinoma cell line SGC-7 901 in vilrothrough multiple mechanisms, and may be a beneficial agent against human adenocarcinoma. AIM:To explore the effects of mifepristone,a progesterone receptor (PR) antagonist,on the proliferation of human gastric adenocarcinoma cell line SGC-7 901 in vitro and the possible mechanisms involved. METHODS:In situ hybridization was used to detect the expression of PR mRNA in SGC-7 901 cells.After treatment with various concentrations of mifepristone (2.5,5,10, 20 μmol/L) at various time intervals,the ultrastructural changes,cell proliferation,cell-cycle phase distribution,and the expression of caspase-3 and Bcl-X_L were analyzed using transmission electron microscopy (TEM),tetrazolium blue (MTT) assay,~3H-TdR incorporation,flow cytometry,and reverse transcription-polymerase chain reaction (RT-PCR). RESULTS:Mifepristone markedly induced apoptosis and inhibited cell proliferation of PR- positive SGC-7 901 cells revealed by TEM,MTr assay and ~3H-TdR incorporation,in a dose- and time-dependent manner.The inhibitory rate was increased from 8.98% to 51.29%.Flow cytometric analysis showed mifepristone dose-dependently decreased cells in S and G_2/M phases,increased cells in G_0/G_1 phase, reduced the proliferative index from 57.75% to 22.83%. In addition,mifepristone up-regulated the expression of caspase-3,and down- regulated the Bcl-X_L expression, dose-dependently. CONCLUSION:Mifepristone effectively inhibited the proliferation of PR-positive human gastric adenocarcinoma cell line SGC-7 901 in vitro through multiple mechanisms,and may be a beneficial agent against human adenocarcinoma.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第18期2628-2631,共4页 世界胃肠病学杂志(英文版)
基金 Supported by the National Key Research Project Foundation of China,No.96-905-02-01,and the National Natural Science Foundation of China,No.39630340
  • 相关文献

参考文献27

  • 1Albert C. Clinical aspects of gastric cancer, in: Rustgi AK, eds.Cas:rointestinal cancer: biology, diagnosis and therapy.Philadelphia: Lippincott Raven 1995:197-216. 被引量:1
  • 2Lu JB, Sun XB, Dai DX, Zhu SK, Chang QL, Liu SZ, Duan WJ.Epidemiology of gastroenterologic cancer in Henan Province,China. World J Gastroenterol 2003; 9:2400-2403. 被引量:1
  • 3Maehara Y, Kakeji Y, Masuda T, Sakoguchi T, lmamura M,Ohgaki K, Taniguchi K, Sakurai M, Futatsugi M, Kimura Y,Nakamura T, Tokunaga E, Oki E, Ushiro S, Watanabe M, Oda S, Tanaka S, Baba H. Treatment of gastric cancer: current state and future prospect. Fukuoka Igaku Zasshi 2003; 94:285-295. 被引量:1
  • 4De Paoli A, Buonadonna A, Boz G, Lombardi D, lnnocente R,Tumolo S, Tosolini G, Rossi C, Trovo MG, Frustaci S. Combined modality treatment for locally advanced gastric cancer.Suppl Tumori 2003; 2:S58-S62. 被引量:1
  • 5Macdonald JS. Chemotherapy Jn the management of gastric cancer. J Chin Oncol 2003; 21: 276s-279s. 被引量:1
  • 6Valentini V, Cellini F, D'Angelillo RM. Combined treatments in gastric cancer: radiotherapy. Suppl Tumori 2003; 2:S39-S44. 被引量:1
  • 7Mahajan DK, London SN. Mifepristone (RU486): a review.Fertil Steril 1997; 68:967-976. 被引量:1
  • 8Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbetal. Int J Oncol 2003; 23:369-380. 被引量:1
  • 9El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998; 51:149-168. 被引量:1
  • 10El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 1998; 49:109-117. 被引量:1

同被引文献22

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部